Finally, future studies could compare the efficacy of Nano-Gefitinib with other targeted therapies or checkpoint inhibitors (e.g., anti-FGL1/LAG-3 blockade) to determine whether combinatorial regimens yield synergistic benefits in cancer therapy. Here, FGL1 is linked to cancer.